# A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer

> **NCT07283198** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 160 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** JSKN033 Injection

## Key facts

- **NCT ID:** NCT07283198
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-10
- **Primary completion:** 2027-08-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07283198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07283198, "A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07283198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*